DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Afinitor; Afinitor 5mg Tablets; Albuterol; Albuterol inhaler; Albuterol nebulizer; Bevacizumab; Celecoxib; Cetuximab; Doxycycline; Doxycycline 100 mg Capsules; EVEROLIMUS; Everolimus; Everolimus (RAD001); Everolimus Oral Product; Glutamine; Hydroxychloroquine; Imatinib; Imatinib Mesylate 400Mg Capsule; Letrozole; Nintedanib; Octreotide; Ofev; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; PFT; Procedure: PFT; RAD001; RAD001 5mg; Rapamycin; Rapamycin, sirolimus; Resveratrol; Saracatinib; Simvastatin; Sirolimus; Sirolimus Oral Product; Sirolimus and Hydroxychloroquine 200 mg; Sirolimus and Hydroxychloroquine 400 mg; Srolimus; Temsirolimus; Valproic Acid; Valproic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00490789 (ClinicalTrials.gov)	October 2005	21/6/2007	Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM	A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: sirolimus	Cardiff University	University of Nottingham;St Georges Hospital Medical School;Royal Sussex County Hospital;The Tuberous Sclerosis Association;Wyeth is now a wholly owned subsidiary of Pfizer	Active, not recruiting	18 Years	65 Years	Both	14	Phase 2	United Kingdom
2	NCT00457808 (ClinicalTrials.gov)	December 2002	6/4/2007	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: Rapamycin , sirolimus	Children's Hospital Medical Center, Cincinnati	The LAM Foundation;Tuberous Sclerosis Alliance	Completed	18 Years	65 Years	Both	25	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00490789
(ClinicalTrials.gov)

October 2005

21/6/2007

Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM

A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis

Tuberous Sclerosis;Lymphangioleiomyomatosis

Drug: sirolimus

Cardiff University

University of Nottingham;St Georges Hospital Medical School;Royal Sussex County Hospital;The Tuberous Sclerosis Association;Wyeth is now a wholly owned subsidiary of Pfizer

Active, not recruiting

18 Years

65 Years

Both

Phase 2

United Kingdom

NCT00457808
(ClinicalTrials.gov)

December 2002

6/4/2007

Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis

Tuberous Sclerosis;Lymphangioleiomyomatosis

Drug: Rapamycin , sirolimus

Children's Hospital Medical Center, Cincinnati

The LAM Foundation;Tuberous Sclerosis Alliance

Completed

18 Years

65 Years

Both

Phase 2

United States